Screener
Viridian Therapeutics, Inc. VRDN Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Change in fair value of derivative liability | (1,190) | — | 6,340 | — |
| Other income (expense), net | 156 | — | (516) | — |
| Total other income (expense), net | (851) | 6,032 | 10,417 | 12,986 |
| Net loss | $(127,119) | $(100,735) | $(232,020) | $(187,647) |
| Net loss per share, basic and diluted, common stock | $(1.05) | $(1.00) | $(1.95) | $(1.87) |
| Weighted-average common shares outstanding, basic and diluted | 107,884,104 | 81,593,463 | 105,063,550 | 81,471,496 |
| Net loss per share, basic and diluted, Series A convertible preferred stock | $(69.72) | $(66.99) | $(129.94) | $(124.93) |
| Weighted-average Series A convertible preferred shares outstanding, basic and diluted | 134,754 | 134,864 | 134,809 | 134,864 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s business segments — net loss?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — net loss of -$127.12M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — net loss decreased by 26.2% year-over-year, from -$100.74M to -$127.12M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — net loss has grown at a 38.2% compound annual growth rate (CAGR), from -$129.87M to -$342.6M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the business segment, calculated as total revenues minus total expenses. For clinical-stage biopharmaceutical companies, this typically reflects the net cash burn required to fund ongoing research and development efforts. It is a primary indicator of the segment's financial sustainability and the pace at which it consumes capital.
Ask your AI about Viridian Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude